Novo Nordisk A/S (NOVO:CA) Q4 2025 Earnings Call February 4, 2026 7:00 AM EST
Company Participants
Michael Novod
Maziar Doustdar – President, CEO & Member of the Management Board
Ludovic Helfgott – Executive VP of Product & Portfolio Strategy and Member of Management Board
David Moore – Executive VP of US Operations & Member of Management Board
Martin Lange – EVP of R&D, Chief Scientific Officer and Member of the Management Board
Karsten Knudsen – Executive VP, CFO & Member of the Management Board
Conference Call Participants
James Quigley – Goldman Sachs Group, Inc., Research Division
Sachin Jain – BofA Securities, Research Division
Richard Vosser – JPMorgan Chase & Co, Research Division
Peter Verdult – BNP Paribas, Research Division
Michael Nedelcovych – TD Cowen, Research Division
Harry Sephton – UBS Investment Bank, Research Division
Thibault Boutherin – Morgan Stanley, Research Division
Carsten Madsen – Danske Bank A/S, Research Division
Simon Baker – Rothschild & Co Redburn, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q4 2025 Novo Nordisk Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your first speaker today, Michael Novod, Head of Investor Relations. Please go ahead.
Michael Novod
Thank you very much, and welcome to this Novo Nordisk Earnings Call for the Full Year of 2025. My name is Michael Novod. I’m the Head of Investor Relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Mike Doustdar; EVP, Product and Portfolio Strategy, Ludovic Helfgott; EVP, U.S. Operations, Dave Moore; EVP, Research and Development and Chief Scientific Officer, Martin Holst Lange; and Chief Financial Officer, Karsten Munk Knudsen. All speakers will be available for the Q&A session.
Today’s call is being webcasted live, and a recording will be made available on our